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1 
COMPOSITIONS FOR TREATING OR 
DELAYING THE ONSET OF HAIR LOSS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
FIG. 4: shows predominant hair re-growth (in white circle) 
in mouse #2 (A) using a topical application of3.0 mg/ml. B) 
mouse prior to experiment. C) shaved area (in white circle) 
Below show immunohistochemistry of3.0 mg/ml (D) where 
5 an overwhelming number ofBrdU positive (green) cells coin-
cides with the area of hair re-growth and 1.5 mg/ml (E) where 
proliferation is at an increase. 
DETAILED DESCRIPTION 
This application is related to U.S. Provisional patent appli-
cation No. 61/097,443; filed Sep. 16, 2008 to which priority is 
claimed under 35 USC 119. This provisional application is 
incorporated herein in its entirety. 10 
Recently, in the course of evaluating factors that influence 
stem cell proliferation, we made a provocative discovery. A 
heterocyclic pyrimidine molecule NBI-18 (2-piperadino-6-
methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3,4-d]pyrimidine 
BACKGROUND 
Alopecia affects millions of men and women annually. 
95% of all hair loss is caused by Androgenic Alopecia (a 
genetically inherited hair loss condition, otherwise known as 
pattern baldness). The remaining 5% of hair loss can be 
associated with a variety of health conditions, stress and 
trauma, diet and nutrition, environmental toxins, and medi-
cations. Currently, five out of 10 men and 21 million women 
will experience hair loss and the psychological affects asso-
ciated with this condition. In the case of Androgenic Alope-
cia, testosterone is converted in the body to DHT (Di-hy-
drotesterone) by the enzyme SAR (5 Alpha-deductase ). DHT 
binds to specific points in the hair follicle called Androgen 
Receptor Sites (ARS) and this causes a mineralization which 
shrinks the diameter of the hair and reduces the time spent in 
the growth cycle, known as the anagen phase. Other known 
types of hair loss can be diagnosed as Telogen Effluvium, 
Traction or Traumatic Alopecia, Alopecia Areata, and Post-
partum Alopecia. Telogen Effluvium produces a premature 
shedding of hair that is in resting or telogen phase. Causes of 
Telogen Effluvium can be contributed to illness, shock, and 
medication and can usually be reversed upon the removal of 
conditions. Traction or Traumatic Alopecia is demonstrated 
by patchy, scattered hair loss and is induced by heating ele-
ments used to dress hairor binding hair with bands; this is also 
reversible by removal of conditions. Alopecia Areata pro-
duces round irregular patchy spots of hair loss and the cause 
is unknown. But the commonality of all types of hair loss is 
the psychological effect it has on the men and women who 
experience these conditions. 
BRIEF DESCRIPTION OF DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
office upon request and payment of the necessary fee. 
FIG. 1 The pictures A-Dare 20 uM sagittal sections of the 
dermal layer of mouse #1 A)Control (50% ETOH) at !Ox B; 
stained with anti-BrdU (green) 1.5 mg/ml NBI-18 at 5x mag-
nification; stained with anti-BrdU (green) and dapi (blue) C) 
3.0 mg/ml NBI-18 at !Ox magnification; stained with anti-
BrdU (green) D) 3.0 mg/ml NBI-18 at !Ox magnification; 
stained with anti-BrdU (green). 
FIG. 2 PicturesA-C are all of mouse #4. A) Prior to experi-
ment (nothing has been done to the animal. B) The circled 
area shows where the hair has been shaved and what appears 
to look like a water drop is the application of solutions prior to 
evaporation (this picture was taken on the first day of appli-
cation). C) The circled area shows where there was a pre-
dominant re-growth of hair. 
FIG. 3. Immunohistochemistry: below A) control B) 3.0 
mg/ml (circled area above in C where there is demonstrative 
hair re-growth. 
15 maleate; Mwt. 349.54), previously described as having pos-
sible neurotrophic activity, can stimulate the proliferation of 
human NSCs in culture. The increase in proliferation was 
dose dependent in animal studies. We found that daily injec-
tions ofNBI-18 for five days led to stable neurogenesis at four 
20 weeks in young and aged rodents alike. There were no dis-
cernible pathological effects, and no symptoms of toxicity 
due to the treatment with NBI-18 throughout the experiment. 
Based on these preliminary findings, we moved towards 
developing a topical application in an attempt to increase cell 
25 proliferation in a similar manner in relation to hair regenera-
tion. C57 BL/6 mice were used to apply different concentra-
tions ofNBI-18 on shaved areas of skin with the incorpora-
tion of BrdU to detect cell proliferation, followed by 
immunohistochemistry. We were able to see an abundant 
30 increase in proliferating cells in all concentrations applied in 
comparison to the control area. More importantly, was the 
visibly complete hair growth that was in the treated areas 
compared to the non-treated areas. NBI-18 promises to be a 
novel compound leading to the development of regenerative 
35 therapeutics that can accelerate hair growth. 
Recently, the inventors became intrigued by several reports 
suggesting that a family of heterocyclic pyrrolopyrimidine 
(PyP) compounds have a variety of growth promoting bio-
logical activities including increasing neurite outgrowth and 
40 repair ofinjured peripheral nerves and muscle. U.S. Pat. Nos. 
4,959,368; 5,976,523. One derivative of interest is heterocy-
clic pyrimidine molecule referred to herein as 'NBI-18' 
(2-piperadino-6-methyl-5-oxo-5,6-dihydro-(7H) pyrrolo-[3, 
4-d]pyrimidine maleate; Mwt. 349.54). In other cell culture 
45 studies using neurons isolated from rodent cortex, NBI-18 
was reported to be active primarily in the presence of various 
growth factors, including bFGF, nerve growth factor, EGF, 
and insulin-like growth factor. U.S. Patent Pub 20030139410. 
The mechanism of action of NBI-18 is not known, although 
50 some evidence implies the activation of the MAPK (mitogen 
activated protein kinase) pathway, a cascade that is also acti-
vated by peptide growth factors. It has been suggested that 
NBI-18 promoted the survival of rodent cortical neurons by 
reducing the rate of apoptosis, as measured by TUNEL 
55 assays. NBI-18 has been tested in isolated animal models-
axon growth in mice and muscle regeneration in rats-with 
no evidence of mechanistic details relating to function. 
Mechanism of action studies to find the drug target, are 
planned as part of our ongoing research. Upon learning about 
60 the availability ofNBI-18 family of molecules, it was hypoth-
esized that the compounds may be involved in the prolifera-
tion process of Stem Cells and the inventors decided to exam-
ine the possible implication for genesis ofKeratinocyte Stem 
Cells (KSCs) or possibly the human bulge cells which pro-
65 vide the niche for KSCs, in animal models. Early evidence 
from rodent studies, suggests that NBI-18 is absorbed well 
after intraperitoneal as well as oral administration and it has a 
US 8,791,128 B2 
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tl/2>>4 h in rat circulation as shown by HPLC analysis. 
NBI-18 can be extracted 24 hours-post-injection from the 
epidermis of treated mice and the compound was not 
mutagenic, as indicated by a third party Ames test. 
Based on the inventors' realizations, the decision was made 5 
to test NBI-18 in a topical application study to induce the 
genesis or re-growth of hair. Varying doses ofNBI-18 [0.75 
mg/ml, 1.5 mg/ml, 3.0 mg/ml, and control (50% ETOH)] was 
delivered in 5 ul drops to shaved locations on the back of C57 
BL/6 mice. The varying doses were given 5 consecutive days 10 
and on day 4 and 5 BrdU (100 mg/kg, ip) was injected. 
Immunohistochemistry suggest a vast increase in Brdu+cells 
throughout the NBI-18 concentrations in comparison to the 
control, which didn't receive NBI-18. However, the most 
impressive data was the visible re-growth of hair in the treated 15 
areas, near to its original length within 7 days. The control or 
untreated areas showed no visible re-growth within the 7 day 
time frame. NBI-18 has proven to produce a desired affect in 
rodent models that show a predominant re-growth of hair 
~f~~gc~:;~~~~a~~~~c::i~~~-~ 1~~~:}! ~~~~:~:fzfI:~!~ 20 
NBI-18 treatment will lead to greater cytogenesis and even-
tually lead to a commercial product that will eradicate hair 
loss. These studies will be further described in the Examples 
provided below. 
Accordingly, in one embodiment, the subject invention 25 
pertains to a method of increasing thickness of hair (i.e. 
number of hair fibers per surface area) and/or number hair 
follicles actively producing hair fibers in a human or nonhu-
man subject that comprises the administration of a hair-en-
hancing composition that contains a hair producing agent 30 
(HPA). U.S. Pat. No. 5,976,523 (523 patent) and U.S. Pat. No. 
4,959,368 ('368 patent) teach a number of compounds that 
may be used as wound healing agents. The '523 patent 
teaches that the wound healing agents described therein act by 
potentiating growth factors and cytokines released in tissues 35 
as a result of injury or wounding of tissues. Essentially, the 
'523 patent teaches that the agents stimulate the migration of 
cells toward the wound. The present inventors have discov-
ered that the same agents actually stimulate the proliferation 
of stem cells, which in tum, led to the discovery that the 
agents may be used in circumstances where tissues have not 40 
been wounded. 
Accordingly, the agents presented in the '523 patent and 
'368 patent are incorporated herein by reference for disclo-
sure ofHPA agents. Also see U.S. Patent Pub 20080124306 
Formulas 1 and 2 as set forth in the' 523 patent are provided: 45 
(1) 
4 
--CH2 0COC2H5 , and X represents NH, =N--CH3 , 
N-COCH3 , =N--COOC2 H5 , N-S02CH3 , =CH2 , 
=CHCH3 , =CHC2H5 , -0- or -S- in which ph stands 
for a phenyl group. 
Typical illustrative compounds of formula (1) include: 
2-piperazino-6-methyl-5-oxo-5,6-dihydro(7H)pyrro-[3,4-d] 
pyrimidine, 
2-( 4-Methylpiperazino-6-methy 1-5-oxo-5 ,6-dihydro-(7H) 
pyrro[3,4-d]pyrimidine, 




2-( 4-Methylpiperidino )-6-methyl-5-oxo-5,6-dihydro(7H) 
pyrro[3,4-d]pyrimidine 


















2-piperazino-6, 7-dimethyl-5-oxo-5 ,6-dihydro(7H)-pyrro [3, 
4-d]pyrimidine, 




2-Piperidino-6, 7, 7-trimethyl-5-oxo-5,6-dihydro-(7H)pyrro 
[3,4-d]pyrimidine, 




Typical illustrative compounds of formula (2) include: 
2-piperazino-7-methy 1-6-oxo-5, 6-dihydro(7H)pyrro-[2,3-d] 
pyrimidine, 










2-( 4-Ethylpiperazino )-7-methyl-6-oxo-5,6-dihydro-(7H) 
pyrro[2,3-d]pyrimidine 




2-( 4-Methylpiperidino )-7-methyl-6-oxo-5,6-dihydro(7H) 
pyrro[2,3-d]pyrimidine 
60 4-(Ethylpiperidino )-7-methyl-6-oxo-5,6-dihydro-(7H)pyrro 
[2,3-d]pyrimidine, 
wherein R1 to R8 independently represent a hydrogen atom, a 65 
lower alkyl (especially C1 -C7 alkyl) group, 
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2-piperazino-4, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2, 
3-d]pyrimidine, 
2-Piperidino-5, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2, 
3-d]pyrimidine, 
2-Piperidino-5, 5, 7-trimethy 1-6-oxo-5 ,6-dihydro-(7H)pyrro 
[2,3-d]pyrimidine, 
2-piperazino-5, 7-dimethyl-6-oxo-5 ,6-dihydro(7H)-pyrro[2, 
3-d]pyrimidine, 






In certain embodiments the pyrimidine derivative of for-
mula (1) is NBI-18, or 2-piperadino-6-methyl-5-oxo-5,6-di-
hydro(7H) pyrrolo[2,3-d]pyrimidine maleate (the C4H4 0 4 
maleate salt), as disclosed in U.S. Pat. No. 4,959,368, incor-
porated by reference herein. In certain in vivo embodiments, 
the pyrimidine derivatives of formulae (I) and (II) is admin-
istered at a concentration of between about 0.01 mg/kg/day to 
50 mg/kg/day, more preferably between about 0.1 mg/kg/day 
to 10 mg/kg/day, even more preferably between about 1 
mg/kg/day to 5 mg/kg/day, and even more preferably about 3 
mg/kg/day. In these embodiments, the pyrimidine derivatives 
6 
organic acids and bases, as is well-known in the art. Typically, 
such salts are more soluble in aqueous solutions than the 
corresponding free acids and bases. 
For topical administration, the active compound( s) may be 
formulated as solutions, gels, ointments, creams, suspen-
sions, etc. as are well-known in the art. 
Systemic formulations include those designed for admin-
istration by injection, e.g., subcutaneous, intravenous, intra-
muscular, intrathecal or intraperitoneal injection, as well as 
10 those designed for transdermal, transmucosal oral or pulmo-
nary administration. 
Useful injectable preparations include sterile suspensions, 
solutions or emulsions of the active compound( s) in aqueous 
or oily vehicles. The compositions may also contain formu-
15 lating agents, such as suspending, stabilizing and/or dispers-
ing agent. The formulations for injection may be presented in 
unit dosage form, e.g., in ampules or in multidose containers, 
and may contain added preservatives. 
Alternatively, the injectable formulation may be provided 
20 in powder form for reconstitution with a suitable vehicle, 
including but not limited to sterile pyrogen free water, buffer, 
dextrose solution, etc., before use. To this end, the active 
compound(s) may dried by any art-known technique, such as 
25 
lyophilization, and reconstituted prior to use. 
For transmucosal administration, penetrants appropriate to 
the barrier to be permeated are used in the formulation. Such 
penetrants are known in the art. 
For oral administration, the pharmaceutical compositions 
may take the form of, for example, tablets or capsules pre-
30 pared by conventional means with pharmaceutically accept-
able excipients such as binding agents (e.g., pregelatinised 
maize starch, polyvinylpyrrolidone or hydroxypropyl meth-
ylcellulose ); fillers (e.g., lactose, microcrystalline cellulose 
or calcium hydrogen phosphate); lubricants (e.g., magnesium 
35 stearate, talc or silica); disintegrants (e.g., potato starch or 
sodium starch glycolate); or wetting agents (e.g., sodium 
lauryl sulfate). The tablets may be coated by methods well 
known in the art with, for example, sugars or enteric coatings. of formulae (I) and (II) is administered for between about 1 
and 60 days, or more preferably between about 1 and 30 days, 
ormorepreferablybetweenabout 1and15 days, orevenmore 
preferably between about 1 and 10 days, or more preferably 
between about 2 and 7 days, or even more preferably about 5 
days. In certain others of these embodiments, the methods 
further comprise the step of administering a growth factor. In 
certain embodiments, the growth factor comprises fibroblast 45 
growth factor, epidermal growth factor or a combination 
thereof. 
Liquid preparations for oral administration may take the 
40 form of, for example, elixirs, solutions, syrups or suspen-
sions, or they may be presented as a dry product for consti-
tution with water or other suitable vehicle before use. Such 
liquid preparations may be prepared by conventional means 
with pharmaceutically acceptable additives such as suspend-
ing agents (e.g., sorbitol syrup, cellulose derivatives or hydro-
genated edible fats); emulsifying agents (e.g., lecithin or aca-
cia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl 
alcohol or fractionated vegetable oils); and preservatives 
(e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). 
Pharmaceutical compositions comprising the active com-
pounds of the invention may be manufactured by means of 
conventional mixing, dissolving, granulating, dragee-making 
levigating, emulsifying, encapsulating, entrapping or lyo-
philization processes. The compositions may be formulated 
in conventional manner using one or more physiologically 
acceptable carriers, diluents, excipients or auxiliaries which 
facilitate processing of the active compounds into prepara-
tions which can be used pharmaceutically. The actual phar-
maceutical composition administered will depend upon the 
mode of administration. Virtually any mode of administration 
may be used, including, for example topical, oral, systemic, 
inhalation, injection, transdermal, etc. 
50 The preparations may also contain buffer salts, flavoring, 
coloring and sweetening agents as appropriate. Preparations 
for oral administration may be suitably formulated to give 
controlled release of the active compound. 
For buccal administration, the compositions may take the 
55 form of tablets, chewing gum or lozenges formulated in con-
ventional manner. 
For rectal and vaginal routes of administration, the active 
compound(s) may be formulated as solutions (for retention 
enemas) suppositories or ointments containing conventional 
60 suppository bases such as cocoa butter or other glycerides. 
The active compound may be formulated in the pharma-
ceutical compositions per se, or in the form of a pharmaceu-
tically acceptable salt. As used herein, the expression "phar-
maceutically acceptable salt" means those salts which retain 
substantially the biological effectiveness and properties of the 65 
active compound and which is not biologically or otherwise 
undesirable. Such salts may be prepared from inorganic and 
For administration by inhalation, the active compound(s) 
can be conveniently delivered in the form of an aerosol spray 
from pressurized packs or a nebulizer, with the use of a 
suitable propellant, e.g., dichlorodifluoromethane, trichlorof-
luoromethane, dichlorotetrafluoroethane, carbon dioxide or 
other suitable gas. In the case of a pressurized aerosol the 
dosage unit may be determined by providing a valve to deliver 
US 8,791,128 B2 
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a metered amount. Capsules and cartridges of e.g. gelatin for 
use in an inhaler or insuffiator may be formulated containing 
a powder mix of the compound and a suitable powder base 




For prolonged delivery, the active compound(s) can be 5 
formulated as a depot preparation, for administration by 
implantation; e.g., subcutaneous, intradermal, or intramuscu-
A total of 16 male C57 BL/6 mice (12 weeks old) weighing 
25-30 g were used to investigate the toxicity ofNBI-18. The 
mice were maintained on a 12-h light/dark cycle, and had free 
access to food and water through the study period. These 
animals were housed four per cage. In this study, animals 
were divided into four groups (four/group). Acute toxicity has 
been tested up to 1000 mg/kg. NBI-18 (0, 100, 300,1000 
lar injection. Thus, for example, the active ingredient may be 
formulated with suitable polymeric or hydrophobic materials 
(e.g., as an emulsion in an acceptable oil) or ion exchange 10 
resins, or as sparingly soluble derivatives; e.g., as a sparingly 
soluble salt mg/kg/day, i.p.) was injected for 7 days and for the control 
group, the same volume of vehicle saline was injected. Bro-
modeoxyuridine (BrdU)(Sigma Chemical Co., St Louis, 
Alternatively, transdermal delivery systems manufactured 
as an adhesive disc or patch which slowly releases the active 
compound(s) for percutaneous absorption may be used. To 
this end, permeation enhancers may be used to facilitate 
transdermal penetration of the active compound(s). Suitable 
transdermal patches are described in for example, U.S. Pat. 
Nos. 5,407,713; 5,352,456; 5,332,213; 5,336,168; 5,290,561; 
5,254,346; 5,164,189; 5,163,899; 5,088,977; 5,087,240; 
5,008,110; and 4,921,475. 
Alternatively, other pharmaceutical delivery systems may 
15 Mo.), was injected (lOOmg/kg/day, i.p.) for the last three days 
(days 5-7). For behavioral testing, rotarod and open field tests 
were used to examine balance and coordination of mice 
before, during and after NBI-18 injection. Also, postural 
reflex and forelimb placing tests were performed to evaluate 
20 the neurological functions for the animals. All the animals 
were anesthetized with pentobarbital (i.p.) 48 h after the last 
BrdU injection and immediately per fused with 4% paraform-
aldehyde fixative. The brains were immediately dissected, 
be employed. Liposomes and emulsions are well-known 
examples of delivery vehicles that may be used to deliver 25 
active compounds(s). Certain organic solvents such as dim-
ethylsulfoxide (DMSO) may also be employed, although usu-
ally at the cost of greater toxicity. 
post fixed for 24 hand processed for immunohistochemistry. 
Results. The animals demonstrated no immediate behav-
ioral or neurological changes in the study. They showed no 
symptoms of toxicity due to the treatment with NBI-18 
throughout the experiment. An Ames was conducted by a 
third party company and the results were consistent showing 
no mutagenesis or toxicity, suggesting that NBI-18 is safe and 
won't have any adverse effects on the mice. 
The pharmaceutical compositions may, if desired, be pre-
sented in a pack or dispenser device which may contain one or 30 
more unit dosage forms containing the active compound(s). 
The pack may, for example, comprise metal or plastic foil, 
such as a blister pack. The pack or dispenser device may be 
accompanied by instructions for administration. 
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EXAMPLE3 
In Vivo Study 
EXAMPLE 1 
Preparation ofNBI-18 Composition 
In preliminary studies, the inventors found that NBI-18 
injections (5 mg/kg) increased proliferation of cells in the 
brain ofrodents. In this study, the inventors determined a dose 
range where keratinogenesis occurs in healthy mice to help us 
learn about the fate of newly formed cells within the epider-
mis. This data enables selection of a relevant dose range for 
treating hair loss conditions such as Androgenic Alopecia, 
Alopecia Areata, Postpartum Alopecia and Telogen Efflu-
vium using a topical application. Normal healthy C57 BL/6 
mice exhibiting natural active behavior were used to test the 
topical application ofNBI-18. In order for us to eliminate 
unnecessary anesthesia, our vehicle of delivery was 50% 
Ethanol (ETOH). NBI-18 was suspended in 50% ETOH 
using the concentrations of 0.75 mg/ml, 1.5 mg/ml, 3.0 
mg/ml, and control (50% ETOH) respectively. 
A. Two C57 BL/6 mice were selected for the topical appli-
cation study ofNBI-18. The mice were prepped by shaving 
four specific locations lateral/dorsal in a circular pattern. 
40 NBI-18 was delivered to the specified areas (right, counter-
clockwise from lowest to highest dose, then control) in con-
centrations of 1.5 mg/ml, 3.0 mg/ml, 6.0 mg/ml and control 
(50% ETOH) respectively. The solutions were applied to the 
center of these locations in a 5 ul dose for 5 consecutive days 
45 and on days 4 and 5 BrdU ( 100 mg/K, ip) was injected. On day 
7 the mice were euthanized using a high dose pentobarbital 
(70 mg/kg, ip) and the treated epidermis was dissected and 
placed into 4% paraformaldehyde fixative for 48 hour 
Immunohistochemistry of epidermis. Epidermal sections 
50 were mounted into square embedding molds with freezing 
medium (O.C.T. compound, Tissue Tek), sliced in 20 uM 
sections then mounted onto adhesive coated slides (Instru-
medics, Inc) via tape transfer method. Slides were washed 
with PBS then placed in 2NHCL for 30 minutes to induce 
55 histone release. Slides were then washed again with PBS, 
then blocked using 3% Donkey serum in PBST for 1 hour. 
Primary anti-body suspended in blocking solution used was 
anti-BrdU (sigma) at 1: 1000 overnight in 4C. Slide were 
washed 3x then placed in secondary anti-body suspended in 
Results. In using 50% ETOH as our delivery vehicle we 
were able to demonstrate through immunohistochemistry, an 
increased population in BrdU positive stained cells. This vis-
ible increase was incurred in all concentrations ofNBI-18 and 
showed a dramatic elevation in BrdU positive stained cells in 
comparison to the control which received just 50% ETOH. 
Although the elevations in BrdU positive stained cells did not 
demonstrate a dose dependent increase as one would expect, 
this could be due to the probability of that each recurring 
application was not placed in exactly the same area on some 65 
of the mice. A more applicable delivery system will be devel-
oped in future studies. 
60 blocking solution, FITC (Jackson ImmunoResearch) at 1 :500 
for 2 hours at room temperature then washed with PBS. Slides 
were mounted using Vectashield with Dapi. Photographs 
were taken using an inverted fluorescent microscope (Leica, 
DMI 6000 B with Q-imaging Retiga exi camera). 
Results. The Control (A) show a much reduced level of 
BrdU signaling along with a nonmigration pattern; the new 
cells are sporadic throughout the tissue sample. All of the 
US 8,791,128 B2 
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NBI-18 treated samples (B-D) showed mass increases of 
newly developed cells but most importantly they demon-
strated an alignment towards migration patterns. FIG. 1. 
B. Four C57 BL/6 mice were selected for the topical appli-
cation study ofNBI-18. The mice were prepped by shaving 
four specific locations lateral/dorsal in a circular pattern. 
NBI-18 was delivered to the specified areas (right, counter-
clockwise from lowest to highest dose, then control) in con-
centrations of 0.75 mg/ml, 1.5 mg/ml, and 3.0 mg/ml, and 
control (50% ETOH) respectively. The solutions were 10 
applied to the center of these locations in a 5 ul dose for 5 
consecutive days and on days 4 and 5 BrdU (100 mg/K, ip) 
was injected. On day 7 the mice were euthanized using a high 
dose pentobarbital (70 mg/kg, ip) and the treated epidermis 
was dissected and placed into 4% paraformaldehyde fixative 15 
for 48 hour. 
10 
appx.1000 days but can range from 2-6 years and it is con-
sidered the "on" phase or growing phase. The catagen phase 
lasts for only 1-2 weeks and during this phase the hair follicle 
shrinks and starts to die; this is known as the transitional 
phase. Telogen is the final phase often referred to as the 
"resting" or "off' phase and this is when the hair follicle 
renews or activates itself and a new hair in the anagen phase 
develops pushing the old hair out. The mechanistic effect of 
NBI-18 has on the stem cell population and how it directly 
effects the hair follicles is still in the process of being eluci-
dated. However, another study using the monoxidil showed 
that in animal studies, topical minoxidil shortens the telogen 
phase, causing premature entry of new hair from resting hair 
follicles into anagen phase, thus producing a mechanistic 
blocking effect of the natural pathways. In order to preserve 
this mechanistic effect, the delivery dosage must continually 
be maintained. In comparison our compound works on the 
physiological pathway of the stem cell environment by 
increasing the proliferation of endogenous cells. Once this 
Immunohistochemistry of epidermis. Epidermal sections 
wer~ mounted into square embedding molds with freezing 
medmm (0.C.T. compound, Tissue Tek), sliced in 20 uM 
sections then mounted onto adhesive coated slides (Instru-
medics, Inc) via tape transfer method. Slides were washed 
with PBS then placed in 2N HCL for 30 minutes to induce 
histone release. Slides were then washed again with PBS, 
then blocked using 3% Donkey serum in PBST for 1 hour. 
Primary anti-body suspended in blocking solution used was 
anti-BrdU (sigma) at 1:1000 overnight in 4C. Slide were 
washed 3x then placed in secondary anti-body suspended in 
blocking solution, FITC (JacksonimmunoResearch) at 1 :500 
for 2 hours at room temperature then washed with PBS. Slides 
were mounted using Vectashield with Dapi. Photographs 
were taken using an inverted fluorescent microscope (Leica, 
DMI 6000 B with Q-imaging Retiga exi camera). 
20 increase is achieved, usually within a 3-5 day treatment 
schedule there is no need to continue using the compound. 
The small molecule NBI-18 bypasses the ethical and tech-
nical issues associated with stem cell transplantation by 
directly coaxing the production of healthy new endogenous 
25 cells. NBI-18 and its variants represent a unique class of 
synthetic heterocyclic compounds that are stable, orally bio-
availability, and easily manufactured. The inventors are able 
to use a compound that works synergistically with natural 
stem cell growth factors to speed up cell proliferation. Such 
30 compounds are a rare and valuable therapeutic candidate. 
This idea delivers an exciting time for everyone. It is a new 
and innovative drug that could change the aesthetics of people 
everywhere. The adverse psychological effects caused hair 
loss will no longer be an in issue in both men and women. 
The disclosures of all cited patent documents, publications 
and references are incorporated herein in their entirety to the 
extent not inconsistent with the teachings herein. It should be 
understood that the examples and embodiments described 
herein are for illustrative purposes only and that various 
Results. In all of the mice there were some varying levels of 
increase in BrdU positive cells in comparison with the con-
trols as shown in the immunohistochemistry. FIG. 3. How- 35 
ever the most visible effect is the actual hair re-growth dem-
onstrated in the pictures of the mice. FIG. 2 (mouse 4) and 
FIG. 4 (mouse 2). Even though the locations ofhair re-growth 
occur sporadically throughout the three concentrations of 
NBI-18 (0.75 mg/ml, 1.5 mg/ml, 3.0 mg/ml.), there is abso-
lutely no visible hair regeneration in the controls within the 
same time constraints. This can be explained by the probabil-
ity of each recurring applications ability was placed in exactly 
the same area. A 5 ul drop onto the back of a moving mouse 
allows for a possible missed location involving topical appli- 45 
cations. However, the data clearly demonstrates the differ-
ences between the control and compound. A next feasible step 
will be to test this compounds efficacy against similar proven 
compounds such as minoxidil (Rogaine). 
40 modifications or changes in light thereof will be suggested to 
persons skilled in the art and are to be included within the 
spirit and purview of this application and the scope of the 
appended claims. 
The invention claimed is: 
1. A method ofinducing hair growth in a patient having hair 
follicles comprising administering a therapeutically effective 
amount of an hair producing (HPA) to said patient, wherein 
said HPA is 2-Piperazino-6-methyl-5-oxo-5,6-dihydro(7H) 
pyrro-[3,4-d]pyrimidine, or a pharmaceutically acceptable 
50 salt thereof, and wherein said administering is topical admin-
istration. 
Discussion related to Examples 1-3. Preliminary studies 
have shown that NBI-18 increases the number of BrdU posi-
tive cells in mice that have received a 5 day consecutive 
topical application of 5 ul doses of0.7 5 mg/ml, 1.5 mg/ml, 3 .0 
mg/ml and 50% ETOH (control). There are three cycles of 
hair growth; the anagen phase (the growing phase), the cat- 55 
agen phase (where hair stops growing) and the Telogen phase 
(which is the resting phase). The anagen phase last for 
2. The method of claim 1, wherein said HPA is in a com-
position further comprising a pharmaceutically acceptable 
carrier. 
3. The method of claim 2, wherein said composition is a 
solution, gel, ointment, cream or suspension. 
* * * * * 
